慢性自发性荨麻疹达标治疗专家共识(2023)

Expert consensus on treat-to-target in chronic spontaneous urticaria(2023)

慢性自发性荨麻疹(CSU)是慢性荨麻疹中最常见的表型。标准剂量、加量或联合的二代抗组胺药是CSU的治疗选择,但约50%的患者对抗组胺治疗抵抗。达标治疗已被证实可提升慢性疾病的管理质量,但目前国内尚未提出CSU达标治疗的理念。我国荨麻疹诊疗及相关领域的31位专家基于国内外最新指南、共识及临床研究、真实世界研究进展,结合专家经验,共同制订CSU达标治疗共识,为临床医生提供指导。

Chronic spontaneous urticaria(CSU)is the most common phenotype of chronic urticaria.Liscenced-dosed,up-dosed,or combined second-generation H1-antihistamines are choices for the treatment of CSU.However,approximately 50%of patients with CSU are resistant to antihistamine therapies.The treat-to-target approach has been proven to improve the quality of chronic disease management,but has not been proposed in CSU in China so far.Based on the latest guidelines,consensus,clinical trials and real-world studies in China and other countries,and combined with experts'clinical experience,31 Chinese experts in the field of urticaria diagnosis and treatment and related fields developed this consensus on treat-to-target in CSU,aiming to provide detailed guidance to clinicians.